BioVersys AG (FRA:W33) ROCE %: -24.78% (As of Dec. 2025)


FRA:W33 BioVersys AG FRA:W33
7 GF Score
Price €28.00
View Full Analysis

What is BioVersys AG ROCE %?

BioVersys AG FRA:W33 -0.71% 7 ROCE % is -24.78% as of Dec. 2025. GuruFocus rates FRA:W33 with a GF Score™ of 7/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BioVersys AG's annualized ROCE % for the quarter that ended in Dec. 2025 was -24.78%.

BioVersys AG  (FRA:W33) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BioVersys AG ROCE % Related Terms

BioVersys AG ROCE % Historical Data

* Premium members only.

The historical data trend for BioVersys AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG ROCE % Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
ROCE %
-69.93 -38.76

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
ROCE % 0.00 -62.19 -38.08 -24.78
FRA:W33
7GF Score
BioVersys AG FRA:W33
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG ROCE % Calculation

BioVersys AG's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-22.223/( ( (37.442 - 10.361) + (97.13 - 9.533) )/ 2 )
=-22.223/( (27.081+87.597)/ 2 )
=-22.223/57.339
=-38.76 %

BioVersys AG's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-22.016/( ( (100.989 - 10.881) + (97.13 - 9.533) )/ 2 )
=-22.016/( ( 90.108 + 87.597 )/ 2 )
=-22.016/88.8525
=-24.78 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -24.78% mean?
BioVersys AG (FRA:W33) has a ROCE % of -24.78% as of Dec. 2025.
Is BioVersys AG's ROCE % too high?
BioVersys AG's current ROCE % is -24.78%. Overall, BioVersys AG has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's ROCE % compare to VRTX and REGN?
BioVersys AG's ROCE % of -24.78% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. BioVersys AG's current ROCE % is -24.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (FRA:W33) has a current ROCE % of -24.78%. The current ROCE % is -24.78%. BioVersys AG's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For BioVersys AG (FRA:W33), the current ROCE % is -24.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKBIOV:Switzerland
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
7GF Score

Get the complete analysis for FRA:W33

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.00
Price